FORM 10-QSB/A

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

(Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

     For the Quarterly period ended March 31, 2000

OR

[ ]  TRANSITION REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

Commission file number 0-14306

                     INTERCELL CORPORATION
                     ---------------------
(Exact name of small business issuer as specified in its charter)

          Colorado                                  84-0928627
          --------                                  ----------
(State or other jurisdiction of                  (I.R.S. employer
 incorporation or organization)                identification number)

          370 17th Street, Suite 3580
            Denver, Colorado 80202
(Address of principal executive offices) (Zip Code)

Issuer's telephone number, including area code:  (303) 592-1010

                       Not applicable
(Former name, former address or former fiscal year, if changed since last
 report)


Indicate by check mark whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.   Yes   X   No
                                          ---      ---


As of May 5, 2000 there were 99,891,188 shares of the registrant's sole class of
common shares outstanding.


Transitional Small Business Disclosure Format          Yes        No   X
                                                            ---       ---







<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                                      INDEX


PART I - FINANCIAL INFORMATION


ITEM 1.  FINANCIAL STATEMENTS                                            PAGE
                                                                         ----

    Independent Accountants' Report                                        1

    Condensed Consolidated Balance Sheet
       March 31, 2000                                                      2

    Condensed Consolidated Statements of Operations
       Three Months and Six Months Ended
       March 31, 2000 and 1999                                             3

    Condensed Consolidated Statement of Changes in Stockholders' Deficit
       Six Months Ended March 31, 2000                                     4

    Condensed Consolidated Statements of Cash Flows
       Six Months Ended March 31, 2000 and 1999                            6

    Notes to Condensed Consolidated Financial Statements
       Six Months Ended March 31, 2000 and 1999                            7


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS                             13


PART II - OTHER INFORMATION                                               16


ITEM 2.  CHANGES IN SECURITIES                                            16

ITEM 6.  EXHIBITS                                                         17


    SIGNATURES                                                            18






























<PAGE>






                         INDEPENDENT ACCOUNTANTS' REPORT


Board of Directors
Intercell Corporation

We have reviewed the accompanying condensed consolidated balance sheet of
Intercell Corporation and subsidiaries as of March 31, 2000, and the related
condensed consolidated statements of operations for the three-month and
six-month periods then ended, and the condensed consolidated statement of
changes in stockholders' deficit and cash flows for the six-month period then
ended. These financial statements are the responsibility of the Company's
management.

We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with generally accepted auditing standards, the objective of which is the
expression of an opinion regarding the financial statements taken as a whole.
Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should
be made to the accompanying condensed consolidated financial statements for them
to be in conformity with generally accepted accounting principles.


GELFOND HOCHSTADT PANGBURN, P.C.


Denver, Colorado
May 16, 2000


































                                        1

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                 MARCH 31, 2000
                                   (UNAUDITED)

<TABLE>
<CAPTION>

Assets
------
<S>                                                            <C>
Current assets:
  Cash and cash equivalents                                    $    445,000
  Prepaid expenses                                                   10,000
                                                               ------------
    Total current assets                                            455,000

Investment in land held for sale                                    500,000
Restricted cash                                                      21,000
                                                                 ----------

       Total assets                                            $    976,000
                                                                 ==========

Liabilities and Stockholders' Deficit
-------------------------------------

Current liabilities:
  Accounts payable                                             $    251,000
  Accrued liabilities                                               242,000
  Accounts payable - related parties                                137,000
  Notes payable - related parties                                    23,000
  Notes payable - other                                              50,000
  Deferred gain on agreement to sell affiliate stock                723,000
  Liabilities of discontinued operations                          3,347,000
                                                                 ----------
    Total current liabilities                                     4,773,000
                                                                 ----------

Commitment and Contingencies

Stockholders' deficit:
  Convertible preferred stock; 10,000,000 shares authorized:
    Series C; 26 shares issued and outstanding
     (liquidation preference of $328,000)                           272,000
    Series D; 1,080 shares issued and outstanding
     (liquidation preference of $3,064,000)                       2,698,000
    Series E; 1,000 shares issued and outstanding
     (liquidation preference of $100,000)                             1,000
  Warrants to acquire common stock                                3,060,000
  Common stock; no par value; 100,000,000 shares authorized
    99,891,188 shares issued and outstanding                     23,461,000
  Additional paid-in capital                                      7,227,000
  Accumulated deficit                                           (39,822,000)
  Receivable from agreement to sell affiliate stock             (   694,000)
                                                                 ----------
      Total stockholders' deficit                               ( 3,797,000)
                                                                 ----------

        Total liabilities and stockholders' deficit            $    976,000
                                                                 ==========

<FN>

See accompanying notes to condensed consolidated financial statements.

</TABLE>


                                        2

<PAGE>

                     INTERCELL CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
            THREE MONTHS AND SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                           Three Months Ended                 Six Months Ended
                                                March 31,                         March 31,
                                          ---------------------             ---------------------
                                          2000             1999             2000             1999
                                          ----             ----             ----             ----
                                                      (As restated,                     (As restated,
                                                        Note 10)                          Note 10)
<S>                                 <C>               <C>              <C>              <C>
General and administrative
  expense                           $    105,000          311,000          189,000          728,000
                                      ----------       ----------       ----------       ----------
Loss from operations                 (   105,000)     (   311,000)     (   189,000)     (   728,000)
                                      ----------       ----------       ----------       ----------
Gain on sale and exchange
  of affiliate stock                     876,000              -            876,000              -
Interest income                            1,000              -              1,000              -
Interest expense                     (     2,000)     (    21,000)     (    25,000)     (    41,000)
                                      ----------       ----------       ----------       ----------
                                         875,000      (    21,000)         852,000      (    41,000)
                                      ----------       ----------       ----------       ----------
Income (loss) from
  continuing operations                  770,000      (   332,000)         663,000      (   769,000)
                                      ----------       ----------       ----------       ----------
Discontinued operations:
  Loss from operations to
   be disposed of                            -                -                -        (    67,000)
                                      ----------       ----------       ----------       ----------
Loss from discontinued operations            -                -                -        (    67,000)
                                      ----------       ----------       ----------       ----------
Net income (loss)                        770,000      (   332,000)         663,000      (   836,000)
Deemed dividend on Series C and D
  preferred stock relating to
  in-the-money conversion terms      (    15,000)     (    15,000)     (    29,000)     (    29,000)
Accrued dividends on Series D
  preferred stock                    (    37,000)     (    38,000)     (    75,000)     (    75,000)
Accretion on Series C
  preferred stock                    (     6,000)     (    29,000)     (    13,000)     (    58,000)
                                      ----------       ----------       ----------       ----------
Net income (loss) applicable to
  common stockholders               $    712,000      (   414,000)         546,000      (   998,000)
                                      ==========       ==========       ==========       ==========
Net income (loss) per share,
  applicable to common stockholders:
   Basic:
    Income (loss)
     from continuing operations     $       0.01      (      0.01)            0.01      (      0.03)
    Loss from discontinued
     operations                      (      0.00)     (      0.00)     (      0.00)     (      0.00)
                                      ----------       ----------       ----------       ----------
    Net income (loss)               $       0.01      (      0.01)            0.01      (      0.03)
                                      ==========       ==========       ==========       ==========
   Diluted:
    Income (loss)
     from continuing operations     $       0.01      (      0.01)            0.00      (      0.03)
    Loss from discontinued
     operations                      (      0.00)     (      0.00)     (      0.00)     (      0.00)
                                      ----------       ----------       ----------       ----------
    Net income (loss)               $       0.01      (      0.01)            0.00      (      0.03)
                                      ==========       ==========       ==========       ==========
Weighted average number of common
  shares outstanding:
    Basic                             98,425,368       39,500,246       89,639,515       38,514,887
                                      ==========       ==========       ==========       ==========
    Diluted                          149,886,863       39,500,246      141,101,010       38,514,887
                                     ===========       ==========      ===========       ==========
<FN>
See accompanying notes to consolidated financial statements.
</TABLE>
                                        3
<PAGE>



                     INTERCELL CORPORATION AND SUBSIDIARIES
      CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
                         SIX MONTHS ENDED MARCH 31, 2000
                                   (UNAUDITED)

<TABLE>
<CAPTION>

                                Convertible
                              Preferred Stock          Warrants to            Common Stock
                              ---------------            Acquire              ------------
                           Shares          Amount      Common Stock     Shares            Amount
                           ------          ----------  ------------     ------            ------
<S>                        <C>          <C>             <C>             <C>            <C>
Balances
  September 30, 1999,       1,150       $ 3,282,000      3,075,000      66,309,089     $22,231,000
  as previously stated

Adjustment to account
  for change from
  consolidation to
  equity method of
  accounting for
  Nanopierce                  -                 -              -               -               -
                            -----         ---------      ---------      ----------      ----------
September 30, 1999,
  as restated               1,150       $ 3,282,000      3,075,000      66,309,089     $22,231,000
Conversion of Series
  C Preferred Stock        (   44)       (  428,000)           -        23,582,099         428,000
Accretion on
  preferred stock             -              13,000            -               -               -
Amortization of
  deemed dividend             -              29,000            -               -               -
Accrual of
  preferred stock
  dividend                    -              75,000            -               -               -
Issuance of Series E
  preferred stock           1,000               -              -               -               -
Receivable from
  agreement to sell
  affiliate stock             -                 -              -               -               -
Settlement of
  convertible
  debentures                  -                 -       (   15,000)     10,000,000         802,000
Net income                    -                 -              -               -               -
                            -----         ---------      ---------      ----------      ----------

Balance as of
  March 31, 2000            2,106       $ 2,971,000      3,060,000      99,891,188     $23,461,000
                            =====         =========      =========      ==========      ==========

                                   (CONTINUED)

</TABLE>















                                        4

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
      CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
                         SIX MONTHS ENDED MARCH 31, 2000
                                   (UNAUDITED)
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                          Receivable
                                            from
                                          Agreement
                           Additional      to Sell                          Total
                            Paid-In       Affiliate     Accumulated     Stockholders'
                            Capital         Stock         Deficit          Deficit
                            -------         -----         -------          -------
<S>                        <C>            <C>           <C>              <C>
Balances
  September 30, 1999,      6,885,000      ( 394,000)    (40,604,000)     (5,525,000)
  as previously stated

Adjustment to account
  for change from
  consolidation to
  equity method of
  accounting for
  Nanopierce                 242,000            -           236,000         478,000
                           ---------       --------      ----------       ---------
September 30, 1999,
  as restated              7,127,000      ( 394,000)    (40,368,000)     (5,047,000)
Conversion of Series
  C Preferred Stock              -              -               -               -
Accretion on
  preferred stock                -              -       (    13,000)            -
Amortization of
  deemed dividend                -              -       (    29,000)            -
Accrual of
  preferred stock
  dividend                       -              -       (    75,000)            -
Issuance of Series E
  preferred stock            100,000            -               -           100,000
Receivable from
  agreement to sell
  affiliate stock                -        ( 300,000)            -        (  300,000)
Settlement of
  convertible
  debentures                     -              -               -           787,000
Net income                       -              -           663,000         663,000
                           ---------       --------      ----------       ---------

Balance as of
  March 31, 2000           7,227,000      ( 694,000)    (39,822,000)     (3,797,000)
                           =========       ========      ==========       =========

<FN>

See accompanying notes to consolidated financial statements.

</TABLE>












                                        5
<PAGE>

                     INTERCELL CORPORATION AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                                   SIX MONTHS ENDED
                                                                      MARCH 31,
                                                                    --------------
                                                                 2000            1999
                                                                 ----            ----
                                                                            (As restated,
                                                                              Note 10)
<S>                                                        <C>              <C>
Cash flows from operating activities:
 Net loss                                                  $    663,000     (   836,000)
 Less loss from discontinued operations                             -            67,000
                                                             ----------      ----------
   Loss from continuing operations                              663,000     (   769,000)
 Adjustments to reconcile net loss to net cash used in
   in operating activities:
  Common stock and warrants issued for expenses                     -           118,000
  Gain on sale and exchange of affiliate stock              (   876,000)            -
  Changes in operating assets and liabilities:
   Increase in prepaid expenses                             (     3,000)            -
   Increase (decrease) in accounts payable
     and accrued liabilities                                (   193,000)        138,000
   Increase in payables to related parties                      143,000             -
   Other                                                            -             3,000
                                                             ----------      ----------
    Net cash used in continuing operations                  (   266,000)    (   510,000)
                                                             ----------      ----------
Cash flows from investing activities:
 Proceeds from sale of stock                                    600,000          11,000
 Other assets                                                       -               -
                                                             ----------      ----------
    Net cash provided by investing activities                   600,000          11,000
                                                             ----------      ----------
Cash flows from financing activities:
 Proceeds from sale of stock by subsidiary                          -           200,000
 Proceeds from notes payable                                        -           146,000
 Repayments of notes payable                                        -       (    72,000)
 Proceeds from sale of convertible preferred stock              100,000             -
                                                             ----------      ----------
    Net cash provided by financing activities                   100,000         274,000
                                                             ----------      ----------
Net increase in cash and cash equivalents                       434,000     (   225,000)
Cash and cash equivalents, beginning of period                   11,000         251,000
                                                             ----------      ----------
Cash and cash equivalents, end of period                   $    445,000          26,000
                                                             ==========      ==========

Supplemental disclosure of cash flow information:
 Cash paid for interest                                    $        -             4,000
                                                             ==========      ==========

Supplemental disclosure of noncash investing and financing activities:

                                                                 2000            1999
                                                                 ----            ----
Acquisition of convertible debt, warrant, accrued
 interest and related payables in exchange for common
 stock and affiliate stock:
   Common stock                                            $    802,000             -
   Affiliate stock                                              276,000             -
Conversion of Series B preferred stock to common stock              -            39,000
Accretion on preferred stock                                     13,000          58,000
Amortization of deemed dividend on preferred stock               29,000          29,000
Accrual of preferred stock dividend                              75,000          75,000

<FN>
See accompanying notes to consolidated financial statements.
</TABLE>
                                        6
<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)


1.  BUSINESS, ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
--------------------------------------------------------------------------

Presentation of Interim Information

The accompanying consolidated financial statements include the accounts of
Intercell Corporation, a Colorado corporation (the Company), and its
subsidiaries Sigma 7 Corporation, (a corporation that filed for voluntary
liquidation under Chapter 7 of the U.S. Bankruptcy Code on December 31, 1998),
Particle Interconnect Corp., and Arizcan Properties, Ltd.  All significant
intercompany accounts and transactions have been eliminated in consolidation.

Additionally as described below, the consolidated financial statements reflect
Nanopierce Technologies, Inc.'s (Nanopierce's) results of operations and cash
flows as a consolidated company from the date of acquisition (February 26, 1998)
through June 30, 1999, and as an investment accounted for under the equity
method of accounting beginning in July 1999, due to a decrease in the Company's
voting ownership interest to below 50% in July 1999.  The Company's investment
in Nanopierce is carried at zero in the Company's financial statements and
therefore the equity method has been suspended and the Company's share of
Nanopierce's losses has not been recorded.

In the opinion of the management of the Company, the accompanying unaudited
consolidated financial statements include all material adjustments, including
all normal and recurring adjustments, considered necessary to present fairly the
financial position of and operating results for the periods presented.  The
financial statements and notes are presented as permitted by Form 10-QSB, and do
not contain certain information included in the Company's last Annual Report on
Form 10-KSB/A for the fiscal year ended September 30, 1999.  It is the Company's
opinion that when the interim statements are read in conjunction with the
September 30, 1999 Annual Report on Form 10-KSB/A, the disclosures are adequate
to make the information presented not misleading.  Interim results are not
necessarily indicative of results for a full year or any future period.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern.  The Company has incurred
significant operating losses, and has a working capital deficiency and a
stockholders' deficit at March 31, 2000.  These conditions raise substantial
doubt about the Company's ability to continue as a going concern.  The
independent auditors' report on the Company's financial statements for the year
ended September 30, 1999 included a "going concern" explanatory paragraph,
meaning the auditors also expressed substantial doubt about the Company's
ability to continue as a going concern.  The financial statements do not include
any adjustments to reflect the possible future effects on the recoverability and
classification of assets or amounts and classifications of liabilities that
might result from the outcome of this uncertainty.

To address its current cash flow concerns, during the three months ended March
31, 2000 the Company sold 1,000 shares of its Series E Preferred Stock for
$100,000 and sold 1,500,000 shares of its stock of Nanopierce for $900,000 (Note
7).  The Company has also been in discussions with investment bankers and
financial institutions attempting to raise funds to support current and future
operations.  This includes attempting to raise additional working capital
through the sale of additional capital stock (Note 3) or through the issuance of
debt.








                                        7

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)

Accounting for investment in Nanopierce and restatement of 1999 consolidated
financial statements

During the quarter ended September 30, 1999, the Company's ownership interest in
Nanopierce was reduced to below 50%.  In the previously issued September 30,
1999, consolidated financial statements, included in the Company's September 30,
1999 Form 10-KSB, the Company reported Nanopierce as a consolidated subsidiary
through September 30, 1999, based on several factors which were believed to
constitute a controlling financial interest in Nanopierce by Intercell,
including common ownership by the President, Director, and CEO of the Company.

Subsequent to the original issuance of the Company's September 30, 1999,
consolidated financial statements, and based upon a further evaluation of the
factors utilized in determining a controlling financial interest, management
determined that beginning in July 1999, the Company's investment in Nanopierce
should be accounted for under the equity method of accounting.

At June 30, 1999, and through September 30, 1999, the Company's investment in
Nanopierce was $0.  Therefore, as a result of the Company's change to the equity
method to account for its investment in Nanopierce, the Company suspended
recognition of its proportionate share of Nanopierce's net loss beginning with
the fourth quarter ended September 30, 1999, which was $236,000, and
accordingly, the Company restated its 1999 consolidated financial statements to
reflect this accounting change, as presented in the Company's Form 10-KSB/A.

In addition, in the previously issued December 31, 1999 condensed consolidated
financial statements, included in the Company's December 31, 1999 Form 10-QSB,
the Company had reported Nanopierce as a consolidated subsidiary through
December 31, 1999.  At September 30, 1999 through December 31, 1999, the
Company's investment in Nanopierce continued to be $0, and the Company continued
to suspend recognition of its proportionate share of Nanopierce's net losses
during the quarter ended December 31, 1999.  Accordingly, the Company's
consolidated financial statements as of and for the quarter ended December 31,
1999 have been restated, and have been presented in a December 31, 1999 Form
10-QSB/A, to reflect the accounting change as follows:

                                       Quarter ended December 31, 1999
                                       -------------------------------

                                     As previously
                                        Reported              As restated
                                        --------              -----------

     Total assets                    $   692,000             $   522,000
     Total liabilities                 6,280,000               5,675,000
     Stockholders' deficit            (5,588,000)             (5,153,000)

     Net loss                         (  904,000)             (  106,000)
     Net loss applicable to
      Common stockholders             (  963,000)             (  165,000)
     Net loss per share applicable
      to common stockholders:         (     0.01)             (     0.00)












                                        8

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)


At March 31, 2000, the Company owns approximately 27% of the outstanding common
stock of Nanopierce.  The summarized financial position and results of
operations of Nanopierce as of and for the periods ended March 31, 2000, was as
follows:

     Current assets                              $ 3,184,000
     Long-term assets:
       Intellectual property         791,000
       Other                          68,000         859,000
                                   ---------       ---------
     Total assets                                $ 4,043,000
                                                   =========

     Current liabilities:
       Notes payable             $   113,000
       Accounts payable and
        accrued expenses             199,000         312,000
                                   ---------
     Long-term liabilities                         3,939,000
     Stockholders' equity                         (  208,000)
                                                   ---------
     Total liabilities and stockholders' equity  $ 4,043,000
                                                   =========

                         Three months ended           Six months ended
                             March 31,               March 31,
                         -------------           -------------
                         2000          1999         2000          1999
                         ----          ----         ----          ----
     Revenues       $       -    $       -     $       -      $      -
     Net loss       $(1,765,000) $(  281,000)  $(2,607,000)   $( 578,000)
     Net loss
      attributable
      to common
      stockholders  $(1,765,000) $(  351,000)  $(2,607,000)   $( 694,000)

Nanopierce is engaged in the design, development and licensing of products using
its intellectual property, the PI Technology.  The PI Technology consists of
patents, pending patent applications, patent applications in preparation, trade
secrets, trade names, and trade marks.  The PI Technology improves electrical,
thermal and mechanical characteristics of electronic products.  Nanopierce has
designated and is commercializing its PI Technology as the Nanopierce Connection
System (NCS) and markets the PI Technology to companies in various industries
for a wide range of applications.  Nanopierce has not realized any royalty
revenue through March 31, 2000.


















                                        9

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)


2.  AUTHORIZED CAPITAL
----------------------

The Company's authorized capital consists of, among other classes of securities,
100,000,000 common shares.  As of May 5, 2000 there are 99,891,188 common shares
issued and outstanding.  In addition, the Company has outstanding certain
classes of securities which are convertible into common shares which would, if
converted, cause the Company to exceed its authorized common shares.  This is
prohibited by the laws of the State of Colorado and therefore until the Company
is able to convene a Special Meeting of the Shareholders pursuant to the proxy
solicitation requirements of Section 14 of the Securities Act of 1934, and the
law of the State of Colorado, it cannot permit such conversions, which means the
Company is or will be in default of certain terms and conditions of such
instruments.  The securities affected consists of the following as of May 5,
2000:

         (1)  26 shares of Series C Preferred shares,
         (2)  1,080 shares of Series D Preferred shares,
         (3)  Warrants convertible into 2,637,450 shares; and
         (4)  Options convertible into 6,927,000 common shares.

The Company intends to promptly prepare and file proxy solicitation materials to
convene a Special Meeting of Shareholders to among other things, increase its
authorized common shares in an amount sufficient to permit the conversion of its
authorized and/or outstanding convertible securities.


3.  INCOME (LOSS) PER SHARE
---------------------------

SFAS No. 128, Earnings per Share, requires dual presentation of basic and
diluted earnings or loss per share (EPS) with a reconciliation of the numerator
and denominator of the basic EPS computation to the numerator and denominator of
the diluted EPS computation.  Basic EPS excludes dilution.  Diluted EPS reflects
the potential dilution that could occur if securities or other contracts to
issue common stock were exercised or converted into common stock or resulted in
the issuance of common stock that then shared in the earnings of the entity.

Basic income (loss) per share of common stock is computed based on the weighted
average number of common shares outstanding during the year.  Diluted EPS
includes the potential conversion of stock options, warrants, convertible debt
and convertible preferred stock during the three and six month periods ended
March 31, 2000.  Stock options, warrants, convertible debt and convertible
preferred stock are not considered in diluted EPS for those periods with net
losses in the calculation, as the impact of the potential common shares
(approximately 132,482,200 shares at March 31, 1999) would be to decrease loss
per share.


4.  BUSINESS RISK
-----------------

The Company and its equity investment, Nanopierce, are subject to risks and
uncertainties common to technology-based companies, including rapid
technological change, dependence on principal products and third-party
technology, new product introductions and other activities of competitors,
dependence on key personnel, and limited operating history.






                                       10

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)


5.  DISCONTINUED OPERATIONS
---------------------------

Liabilities of discontinued operations at March 31, 2000, consist of Sigma
liabilities as follows:

Accounts payable and accrued liabilities                $   986,000
Notes payable                                             2,240,000
Other liabilities                                           121,000
                                                         ----------
                                                        $ 3,347,000
                                                         ==========

The liabilities of $3,347,000 remain on the books of Sigma as of March 31, 2000,
pending a final judgment from the U.S. Bankruptcy Court as to the disposition of
these liabilities.  Management's estimates of these liabilities have not changed
during the period ended March 31, 2000.

Notes payable of discontinued operations primarily consist of $1,700,000, 10%,
unsecured notes payable issued in a 1997 private placement, originally due in
October 1998.

The $67,000 loss from discontinued operations for the six months ended March 31,
1999 represents accrued interest on the notes payable to the date of the
bankruptcy filing.


6.  AFFILIATE STOCK SALES
-------------------------

During the three months ended March 31, 2000, the Company agreed to sell
1,500,000 shares of its restricted Nanopierce common shares to the holders of
the Series E Preferred Stock for $900,000.  At March 31, 2000, $600,000 of the
$900,000 had been received in cash, and the remaining $300,000 was receivable,
and was secured by 60,000 shares of Nanopierce.  The Company recognized a
$600,000 gain on the sale of the Nanopierce stock, which represented the
difference between the carrying value of the Company's investment in the
Nanopierce stock ($0) and the cash received.  Due to the uncertainty regarding
the ultimate realization of the gain on the receivable portion of the
transaction, the receivable balance is classified as a reduction to
stockholders' equity (deficit) at March 31, 2000, and a liability has been
recorded for the unrealized gain.

During the three months ended March 31, 2000, the Company exchanged 170,000
restricted shares of Nanopierce as partial payment on the Company's convertible
debentures of $826,000 (Note 7).  A gain of $276,000 was recognized on the
disposition of these shares.


7.  CONVERTIBLE DEBENTURES
--------------------------

During the three months ended March 31, 2000, the Company acquired the
outstanding convertible debentures of $826,000, including accrued interest and a
related warrant to purchase 400,000 shares of common stock of the Company in
exchange for 10,000,000 shares of the Company's common stock and 170,000 shares
of the Company's Nanopierce shares.  This transaction released certain assets of
the Company which had previously been pledged as collateral on the convertible
debentures.




                                       11

<PAGE>




                     INTERCELL CORPORATION AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                    SIX MONTHS ENDED MARCH 31, 2000 AND 1999
                                   (UNAUDITED)


8.  STOCKHOLDERS' EQUITY
------------------------

During the six months ended March 31, 2000, the Company issued 23,582,099 shares
of common stock in connection with Series C Preferred Stock conversions and
issued 10,000,000 shares of common stock as partial satisfaction of the
Company's convertible debentures.

On February 14, 2000, the Company's Board of Directors authorized the issuance
of 1,000 shares of a newly created Series E Convertible Preferred Stock and
approved a plan to re-incorporate the Company from Colorado to Nevada subject to
shareholder approval.

The Series E Preferred shares were issued in March 2000, bear a cumulative
dividend of six percent per year and are convertible into common stock after the
Company is re-incorporated in Nevada, after a reverse split of the shares of the
Nevada Corporation is effective, and after the authorized common shares of the
Nevada Company has been increased as considered necessary.  The Series E
Preferred Stock is convertible into common stock equal to five percent of the
common stock outstanding of the Company on a fully diluted basis.  The intrinsic
value of the beneficial conversion feature of the Series E Convertible Preferred
Stock was $100,000 and is being amortized to dividends over the period from
issuance to the earliest date of conversion which is July 15, 2000.  The Series
E Preferred Stock shall have 120,000 votes per Series E Preferred share.  The
votes on the Series E shares shall be identical in every other respect to the
voting rights of the holders of common stock entitled to vote.


9.  LITIGATION
--------------

The Company is involved in various claims and legal actions arising in the
ordinary course of business.  In the opinion of management, the ultimate
disposition of these matters will not have a material adverse effect on the
financial statements of the Company.




























                                       12

<PAGE>




ITEM 2.  MANAGEMENTS'S DISCUSSION AND ANALYSIS


GENERAL

The statements contained in this Form 10-QSB/A, if not historical, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties that could
cause actual results to differ materially from the results, financial or
otherwise, or other expectations described in such forward-looking statements.
Any forward-looking statement or statements speak only as of the date on which
such statements were made, and the Company undertakes no obligation to update
any forward-looking statement to reflect events or circumstances after the date
on which such statements are made or reflect the occurrence of unanticipated
events.  Therefore, forward-looking statements should not be relied upon as
prediction of actual future results.

The independent auditors' report on the Company's financial statements for the
year ended September 30, 1999 included a "going concern" explanatory paragraph,
that describes substantial doubt about the Company's ability to continue as a
going concern.  Management's plans in regard to the factors prompting the
explanatory paragraph are discussed below and also in Note 1 of the audited
financial statements contained in the Company's Annual Report on Form 10-KSB/A
for the fiscal year ended September 30, 1999.

Intercell Corporation discontinued all operations of its majority owned
subsidiary Sigma 7 Corporation, a manufacturer of memory modules located in San
Diego, CA, on June 5, 1998.  Sigma 7 Corporation subsequently filed for
liquidation under Chapter 7 of the United States Bankruptcy Code on December 30,
1998.  The liabilities of $3,347,000 remain on the books pending a final
judgment from the U.S. Bankruptcy Court as to the disposition of these
liabilities.

At March 31, 2000, the Company owns approximately 27% of the outstanding common
stock of Nanopierce Technologies, Inc.  During the quarter ended September 30,
1999, the Company's ownership interest in Nanopierce was reduced to below 50%.
In the previously issued September 30, 1999, consolidated financial statements,
included in the Company's September 30, 1999 Form 10-KSB, the Company reported
Nanopierce as a consolidated subsidiary through September 30, 1999, based on
several factors which were believed to constitute a controlling financial
interest in Nanopierce by Intercell, including common ownership by the
President, Director, and CEO of the Company.

Subsequent to the original issuance of the Company's September 30, 1999,
consolidated financial statements, and based upon a further evaluation of the
factors utilized in determining a controlling financial interest, management
determined that beginning in July 1999, the Company's investment in Nanopierce
should be accounted for under the equity method of accounting.

At June 30, 1999, and through September 30, 1999, the Company's investment in
Nanopierce was $0.  Therefore, as a result of the Company's change to the equity
method to account for its investment in Nanopierce, the Company suspended
recognition of its proportionate share of Nanopierce's net loss beginning with
the fourth quarter ended September 30, 1999, which was $236,000.  As a result,
the Company has restated its 1999 consolidated financial statements to reflect
this accounting change, as presented in the Company's Form 10-KSB/A.













                                       13

<PAGE>




In addition, in the previously issued December 31, 1999 condensed consolidated
financial statements, included in the Company's December 31, 1999 Form 10-QSB,
the Company had reported Nanopierce as a consolidated subsidiary through
December 31, 1999.  At September 30, 1999 through December 31, 1999, the
Company's investment in Nanopierce continued to be $0, and the Company continued
to suspend recognition of its proportionate share of Nanopierce's net losses
during the quarter ended December 31, 1999.  Accordingly, the Company's
consolidated financial statements as of and for the quarter ended December 31,
1999 have been restated, and have been presented in a December 31, 1999 Form
10-QSB/A, to reflect the accounting change as follows:

                                  Quarter ended December 31, 1999
                                  -------------------------------

                                     As previously
                                        Reported              As restated
                                        --------              -----------

     Total assets                    $   692,000             $   522,000
     Total liabilities                 6,280,000               5,675,000
     Stockholders' deficit            (5,588,000)             (5,153,000)

     Net loss                         (  904,000)             (  106,000)
     Net loss applicable to
      Common stockholders             (  963,000)             (  165,000)
     Net loss per share applicable
      to common stockholders:         (     0.01)             (     0.00)

The Company, through its 27% - owned affiliate, Nanopierce Technologies, Inc.,
is currently engaged in the design, development and licensing of products using
its patented particle interconnect technology.

The Company, through its 27 percent owned affiliate, Nanopierce Technologies,
Inc., is currently engaged in the design, development and licensing of products
using its patented particle interconnect technology.


RESULTS OF OPERATIONS


The Company had no revenue from continuing operations for the six months ended
March 31, 2000 and 1999.

The Company had net income of $663,000 for the six months ended March 31, 2000
compared to a net loss of $836,000 for the six months ended March 31, 1999.
General and administrative expenses decreased to $189,000 for the six months
ended March 31, 2000 from $728,000 for the six months ended March 31, 1999.
This decrease is primarily due to expenses incurred by Nanopierce in the 1999
period (as described elsewhere, the Company consolidated the operations of
Nanopierce through June 30, 1999).  During the three months and six months ended
March 31, 2000 the Company realized gains on the sales of its Nanopierce stock
of $876,000.  There were no gains in the prior year periods.  Interest expense
decreased in the 2000 period as compared to the 1999 period as a result of the
Company purchasing its outstanding convertible debt.  For the three months and
six months ended March 31, 2000 no loss has been recorded for the Company's
equity in losses of Nanopierce because the Company's investment in Nanopierce
is carried at zero and therefore the equity method has been suspended.












                                       14

<PAGE>




LIQUIDITY AND FINANCIAL CONDITION

The Company has a working capital deficit of $4,318,000 at March 31, 2000
compared to a working capital deficit of $5,575,000 at September 30, 1999.

The Company's liabilities decreased to $4,773,000 at March 31, 2000 compared to
$5,585,000 at September 30, 1999.  The decrease was due in part to a decrease of
$826,000 in convertible debentures which were repurchased by the Company.

Without gains on the sale of its Nanopierce stock, the Company's current
operations are not generating positive cash flow.  To address its current cash
flow concerns, during the three months ended March 31, 2000 the Company sold
1,000 shares of its Series E Preferred Stock for $100,000 and sold 1,500,000
shares of its stock of Nanopierce for cash of $900,000 of which $600,000 was
received by March 31, 2000.  The Company also exchanged 170,000 shares of
Nanopierce, value at $276,000 as part consideration for the repurchase of the
Company's convertible debentures.

Since the Company's operations are not sufficient to fund the Company's capital
requirements, the Company may enter into a revolving loan agreement with a
financial institution, or attempt to raise additional capital through the sale
of additional capital stock (Notes 2 and 8), sale of additional Nanopierce
stock, or through the issuance of debt.  At the present time the Company does
not have a revolving loan agreement with any financial institution nor can the
Company provide assurances that it will be able to raise funds through issuance
of debt or equity in the Company.


RECENTLY ISSUED ACCOUNTING PRONOUNCEMENT


In June 1998, the Financial Accounting Standard Board (FASB) issued SFAS No.
133, Accounting for Derivative Instruments and Hedging Activities.  This
statement, as amended by SFAS No. 137, is effective for fiscal years beginning
after June 15, 2000.  Currently, the Company does not have any derivative
financial instruments and does not participate in hedging activities; therefore,
management believes that SFAS No. 133 will not impact the Company's financial
statements.































                                       15

<PAGE>




                           PART II - OTHER INFORMATION


                      ITEM 1.  LEGAL PROCEEDINGS


On July 1, 1998, the Company was served a summons and complaint naming it, its
subsidiary, Sigma and others affiliated with the Company, by Classic Trading,
Inc., a California corporation, with the Superior Court of the State California,
Count of Orange, CV 796047 (the " Classic Trading Lawsuit").  Classic Trading,
Inc. alleges breach of contact and believes that it is owed $135,000.00.  The
Company has filed an answer denying the allegations.  The litigation has not
been further prosecuted since then.


                      ITEM 2.     CHANGES IN SECURITIES

The Company made the following unregistered sales of its securities from October
1,  1999  to  March  31,  2000.

<TABLE>
<CAPTION>

DATE OF SALE     TITLE OF SECURITIES       SHARES       CONSIDERATION           PURCHASER
------------     -------------------       ------       -------------           ---------
<S>                    <C>               <C>           <C>                    <C>
10/05/99               Common            12,218,767    Series C Conversion    Queensway Financial Group
10/26/99               Common             3,333,333    Series C Conversion    The Gifford Fund, Ltd.
12/31/99               Common             2,071,416    Series C Conversion    Capital Venture Group
 1/03/00               Common             9,000,000    Payment of Debt        Augustine Fund, LP
 1/11/00               Common             2,909,119    Series C Conversion    Capital Venture Group
 1/14/00               Common             1,000,000    Payment of Debt        Augustine Fund, LP
 1/20/00               Common             3,019,464    Series C Conversion    Capital Venture Group

</TABLE>


                       EXEMPTION FROM REGISTRATION CLAIMED


All of the sales by the Company of its unregistered securities were made by the
Company in reliance upon Section 4(2) of the Act.  All of the individuals and/or
entities listed above that purchased the unregistered securities were all known
to the Company and its management, through pre-existing business relationships,
as long standing business associates, friends, and employees.  All purchasers
were provided access to all material information which they requested and all
information necessary to verify such information and were afforded access to
management of the Company in connection with their purchases.  All purchasers of
the unregistered securities acquired such securities for investment and not with
a view toward distribution, acknowledging such intent to the Company.  All
certificates or agreements representing such securities that were issued
contained restrictive legends, prohibiting further transfer of the certificates
or agreements representing such securities, without such securities either being
first registered or otherwise exempt from registration in any further resale or
disposition.














                                       16

<PAGE>




                      ITEM 6.     EXHIBITS AND REPORTS ON FORM 8-K


EXHIBITS

Exhibit 11     Statement of Computation of Earnings per Share
Exhibit 27     Financial Data Schedule


REPORTS ON FORM 8-K

On April 10, 2000 the Company filed Form 8-K reporting the authorization and
issuance of Series E Preferred Stock, the temporary change in control of the
Company and other events.























































                                       17

<PAGE>




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                    INTERCELL CORPORATION
                                    (REGISTRANT)

Date:  August 29, 2000              By: /s/  Paul H. Metzinger
                                    --------------------------
                                        Paul H. Metzinger, President,
                                        Chief Executive Officer &
                                        Chief Financial Officer





















































                                       18

<PAGE>